The combination was approved for medical use in the United States in 2007.[4] In 2021, it was the 154th most commonly prescribed medication in the United States, with more than 3million prescriptions.[9][10] It is available as a generic medication.[11][12]
In the European Union, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes; in combination with a sulfonylurea as an adjunct to diet and exercise "in people inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea; as triple combination therapy with a peroxisome proliferator-activated receptor (PPAR) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in people inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist; and as add-on to insulin as an adjunct to diet and exercise to improve glycemic control in people when stable dosage of insulin and metformin alone do not provide adequate glycemic control."[6]
In December 2020, the U.S. Food and Drug Administration (FDA) approved labeling changes stating that Januvia (sitagliptin), Janumet (sitagliptin and metformin hydrochloride), and Janumet XR (sitagliptin and metformin hydrochloride extended-release) are not proven to improve glycemic (blood sugar) control in children aged 10 to 17 with type 2 diabetes.[13] The drugs are approved to improve blood sugar control in adults aged 18 and older with type 2 diabetes.[13]
Society and cultureedit
Brand namesedit
As of 2018, the combination is marketed under several brand names, including Efficib, Janmet, Januet, Janumet, Jznumet, Ristaben Met, Ristfor, Siglimet, Sitamet, Sitar-M, Sliptin-M, Treviamet, Velmetia, Istamet, Emsita, Sitaglyn, Sitazit-M and Zaxoran.[14]
Referencesedit
^ ab"Metformin / sitagliptin Use During Pregnancy". Drugs.com. from the original on 19 April 2019. Retrieved 19 April 2019.
^"Sitagliptin/metformin Sandoz XR (Sandoz Pty Ltd)". Therapeutic Goods Administration (TGA). 2 June 2023. Retrieved 10 September 2023.
^"Janumet 50 mg/1000 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 25 November 2020. from the original on 26 October 2020. Retrieved 5 December 2020.
^ abcdef"Janumet- sitagliptin and metformin hydrochloride tablet, film coated". DailyMed. 12 August 2019. from the original on 9 June 2021. Retrieved 5 December 2020.
^ ab"Janumet XR- sitagliptin and metformin hydrochloride tablet, film coated, extended release". DailyMed. from the original on 29 October 2020. Retrieved 5 December 2020.
^ ab"Janumet EPAR". European Medicines Agency (EMA). from the original on 9 June 2021. Retrieved 5 December 2020.
^ abcBritish national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 682. ISBN9780857113382.
^Hayes J, Anderson R, Stephens JW (2016). "Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy". Drug Design, Development and Therapy. 10: 2263–70. doi:10.2147/DDDT.S93076. PMC4958358. PMID 27486305.
^"The Top 300 of 2021". ClinCalc. from the original on 15 January 2024. Retrieved 14 January 2024.
^"Metformin; Sitagliptin - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
^"Sitagliptin / Metformin hydrochloride Accord EPAR". European Medicines Agency (EMA). 17 May 2022. from the original on 3 August 2022. Retrieved 3 August 2022.
^"Sitagliptin / Metformin hydrochloride Sun: Pending EC decision". European Medicines Agency (EMA). 26 January 2023. from the original on 27 January 2023. Retrieved 28 January 2023.
^ ab"New studies show diabetes drug not proven to improve blood sugar control in pediatric patients". U.S. Food and Drug Administration. 4 December 2020. from the original on 4 December 2020. Retrieved 5 December 2020. This article incorporates text from this source, which is in the public domain.
^"International brands for Sitagliptin/metformin". Drugs.com. from the original on 23 August 2019. Retrieved 3 September 2018.
sitagliptin, metformin, sold, under, brand, name, janumet, among, others, fixed, dose, combination, anti, diabetic, medication, used, treat, type, diabetes, used, those, whose, blood, sugar, controlled, with, metformin, sulfonylurea, taken, mouth, combination,. Sitagliptin metformin sold under the brand name Janumet among others is a fixed dose combination anti diabetic medication used to treat type 2 diabetes 7 It may be used in those whose blood sugar is not controlled with metformin and a sulfonylurea 7 8 It is taken by mouth 7 Sitagliptin metforminCombination ofSitagliptinDipeptidyl peptidase 4 inhibitorMetforminBiguanideClinical dataTrade namesJanumet Januet othersAHFS Drugs comProfessional Drug FactsLicense dataUS DailyMed Sitagliptin and metforminPregnancycategoryAU C 1 Routes ofadministrationBy mouthATC codeA10BD07 WHO Legal statusLegal statusAU S4 Prescription only 2 UK POM Prescription only 3 US only 4 5 EU Rx only 6 In general Prescription only IdentifiersKEGGD10261Common side effects include diarrhea headache and upper respiratory tract infections 4 Serious side effects may include lactic acidosis pancreatitis low blood sugar heart failure joint pain and allergic reactions 4 It has not been properly studied in women who are pregnant or breastfeeding 1 It contains sitagliptin a dipeptidyl peptidase 4 inhibitor and metformin a biguanide 4 The combination was approved for medical use in the United States in 2007 4 In 2021 it was the 154th most commonly prescribed medication in the United States with more than 3 million prescriptions 9 10 It is available as a generic medication 11 12 Contents 1 Medical uses 2 Society and culture 2 1 Brand names 3 ReferencesMedical uses editIn the United States sitagliptin metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes 4 5 In the European Union sitagliptin metformin is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes in combination with a sulfonylurea as an adjunct to diet and exercise in people inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea as triple combination therapy with a peroxisome proliferator activated receptor PPAR agonist i e a thiazolidinedione as an adjunct to diet and exercise in people inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist and as add on to insulin as an adjunct to diet and exercise to improve glycemic control in people when stable dosage of insulin and metformin alone do not provide adequate glycemic control 6 In December 2020 the U S Food and Drug Administration FDA approved labeling changes stating that Januvia sitagliptin Janumet sitagliptin and metformin hydrochloride and Janumet XR sitagliptin and metformin hydrochloride extended release are not proven to improve glycemic blood sugar control in children aged 10 to 17 with type 2 diabetes 13 The drugs are approved to improve blood sugar control in adults aged 18 and older with type 2 diabetes 13 Society and culture editBrand names edit As of 2018 the combination is marketed under several brand names including Efficib Janmet Januet Janumet Jznumet Ristaben Met Ristfor Siglimet Sitamet Sitar M Sliptin M Treviamet Velmetia Istamet Emsita Sitaglyn Sitazit M and Zaxoran 14 References edit a b Metformin sitagliptin Use During Pregnancy Drugs com Archived from the original on 19 April 2019 Retrieved 19 April 2019 Sitagliptin metformin Sandoz XR Sandoz Pty Ltd Therapeutic Goods Administration TGA 2 June 2023 Retrieved 10 September 2023 Janumet 50 mg 1000 mg film coated tablets Summary of Product Characteristics SmPC emc 25 November 2020 Archived from the original on 26 October 2020 Retrieved 5 December 2020 a b c d e f Janumet sitagliptin and metformin hydrochloride tablet film coated DailyMed 12 August 2019 Archived from the original on 9 June 2021 Retrieved 5 December 2020 a b Janumet XR sitagliptin and metformin hydrochloride tablet film coated extended release DailyMed Archived from the original on 29 October 2020 Retrieved 5 December 2020 a b Janumet EPAR European Medicines Agency EMA Archived from the original on 9 June 2021 Retrieved 5 December 2020 a b c British national formulary BNF 76 76 ed Pharmaceutical Press 2018 p 682 ISBN 9780857113382 Hayes J Anderson R Stephens JW 2016 Sitagliptin metformin fixed dose combination in type 2 diabetes mellitus an evidence based review of its place in therapy Drug Design Development and Therapy 10 2263 70 doi 10 2147 DDDT S93076 PMC 4958358 PMID 27486305 The Top 300 of 2021 ClinCalc Archived from the original on 15 January 2024 Retrieved 14 January 2024 Metformin Sitagliptin Drug Usage Statistics ClinCalc Retrieved 14 January 2024 Sitagliptin Metformin hydrochloride Accord EPAR European Medicines Agency EMA 17 May 2022 Archived from the original on 3 August 2022 Retrieved 3 August 2022 Sitagliptin Metformin hydrochloride Sun Pending EC decision European Medicines Agency EMA 26 January 2023 Archived from the original on 27 January 2023 Retrieved 28 January 2023 a b New studies show diabetes drug not proven to improve blood sugar control in pediatric patients U S Food and Drug Administration 4 December 2020 Archived from the original on 4 December 2020 Retrieved 5 December 2020 nbsp This article incorporates text from this source which is in the public domain International brands for Sitagliptin metformin Drugs com Archived from the original on 23 August 2019 Retrieved 3 September 2018 Portal nbsp Medicine nbsp This drug article relating to the gastrointestinal system is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Sitagliptin metformin amp oldid 1208834800, wikipedia, wiki, book, books, library,
